I think you're underestimating the outstanding ABSSSI phase 2b, QIDP designation, heady Cubicin buyout, and near-term partnership and phase 3 prospects in December 2014.
Kevetrin was low on the list of stock price drivers at that time.
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links